All In Biotech

NDA 050689 · Pfizer

Mycobutin

Rifabutin · Oral · Rifamycin Antimycobacterial

NovelPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Nov 20, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1992

Dec 23, 1992

Approved uses

1

Original approval plus efficacy supplements

Registered trials

91

18 Phase 3, 5 recruiting

FAERS reports

2,755

2,287 serious, 310 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 1, 2026.

INDICATIONS AND USAGE Rifabutin capsules are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection.

Mechanism: Mechanism of Action Rifabutin inhibits DNA-dependent RNA polymerase in susceptible strains of Escherichia coli and Bacillus subtilis but not in mammalian cells. In resistant strains of E. coli , rifabutin, like rifampin, did not inhibit this enzyme. It is not known whether rifabutin inhibits DNA-dependent RNA polymerase in Mycobacterium avium or in M. intracellulare which comprise M. avium complex (MAC).

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 23, 1992 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
  • MYCOBUTIN · RIFABUTIN 150MG · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Rifabutin" as an intervention, any sponsor and status, largest first.

All 91 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug interaction270
  • drug ineffective268
  • off label use223
  • nausea171
  • pyrexia163
  • drug resistance161
  • mycobacterium avium complex infection150
  • drug intolerance129
  • neutropenia120
  • immune reconstitution inflammatory syndrome119
  • product use in unapproved indication109
  • diarrhoea100

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200425
200525
200627
200727
200829
200959
201048
201159
201264
201342
201426
201564
201694
201799
2018173
2019135
2020152
2021168
2022206
2023297
2024344
2025390
2026202

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Mycobutin (Rifabutin)

2024 spending

$12K

Beneficiaries

16

17 claims

Per beneficiary

$721

$16.61 per unit

View as table
YearSpending
2020$32,219
2021$89,640
2022$47,124
2023$19,148
2024$11,530

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 169 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.